Claims for Patent: 7,902,240

Summary for Patent: 7,902,240

Title:	Substituted pyrazole and triazole compounds as KSP inhibitors
Abstract:	Disclosed are new substituted pyrazole and triazole compounds of Formula (I) and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses thereof: ##STR00001##
Inventor(s):	Xia; Yi (Palo Alto, CA), Mendenhall; Kris (Concord, CA), Barsanti; Paul A. (Pleasant Hill, CA), Walter; Annette O. (Mill Valley, CA), Duhl; David (Oakland, CA), Renhowe; Paul A. (Danville, CA)
Assignee:	Novartis AG (Basel, CH)
Application Number:	11/937,426
Patent Claims:	1. A compound of Formula (I) or a pharmaceutically acceptable salt, ester, or prodrug thereof: ##STR00171## wherein: R.sup.1 is selected from the group consisting of alkyl and substituted alkyl; R.sup.2 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl; R.sup.3 is selected from the group consisting of -L.sup.1-A.sup.1, wherein L.sup.1 is selected from the group consisting of --C(O)--, --C(S)--, and --S(O), and A.sup.1 is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, and NR.sup.8R.sup.9; R.sup.4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl; or R.sup.3 and R.sup.4 together with the nitrogen atom bound thereto join to form a five to seven membered heterocycloalkyl or substituted heterocycloalkyl group where optionally one additional ring atom is selected from the group consisting of O, S, or NR.sup.11; X is N; R.sup.6 is selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, all of which may be optionally substituted with --(R.sup.10).sub.m where R.sup.10 is as defined herein, m is 1, 2, 3, or 4, and each R.sup.10 may be the same or different when m is 2, 3, or 4; R.sup.7 is -L.sup.2-A.sup.2 wherein L.sup.2 is C.sub.1-C.sub.5 alkylene and A.sup.2 is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl, provided that R.sup.7 is not attached to X; R.sup.8 is selected from the group consisting of hydrogen and alkyl; R.sup.9 is selected from the group consisting of hydrogen, hydroxy, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl; or R.sup.8 and R.sup.9 together with the nitrogen atom pendent thereto join to form a heterocycloalkyl or substituted heterocycloalkyl; R.sup.10 is selected from the group consisting of cyano, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, --CF.sub.3, alkoxy, substituted alkoxy, halo, and hydroxy; and R.sup.11 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, --SO.sub.2alkyl, and --SO.sub.2 substituted alkyl. 2. A compound of claim 1, wherein R.sup.1 and R.sup.2 are methyl. 3. A compound of claim 1, having Formula (Ia)-(Ie) or a pharmaceutically acceptable salt, ester, or prodrug thereof: ##STR00172## 4. A compound of claim 1, wherein L.sup.1 is --CO--. 5. A compound of claim 1, having Formula (II) or a pharmaceutically acceptable salt, ester, or prodrug thereof: ##STR00173## wherein: R.sup.1 is selected from the group consisting of alkyl and substituted alkyl; R.sup.4 is alkyl substituted with one to five substituents selected from the group consisting of hydroxy, alkoxy, substituted alkoxy, amino, substituted amino, acylamino, halo, nitrogen-containing heterocycloalkyl, substituted nitrogen-containing heterocycloalkyl, nitrogen-containing heteroaryl, and substituted nitrogen-containing heteroaryl; A.sup.1 is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, and NR.sup.8R.sup.9; or A.sup.1 and R.sup.4 together with the atoms bound respectively thereto join to form a heterocycloalkyl or substituted heterocycloalkyl group where optionally one additional ring atom is selected from the group consisting of O, S, or NR.sup.11; X is N; R.sup.7 is -L.sup.2-A.sup.2 wherein L.sup.2 is C.sub.1-C.sub.5 alkylene and A.sup.2 is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl; R.sup.8 is selected from the group consisting of hydrogen and alkyl; R.sup.9 is selected from the group consisting of hydrogen, hydroxy, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, and substituted heterocycloalkyl; or R.sup.8 and R.sup.9 together with the nitrogen atom pendent thereto join to form a heterocycloalkyl or substituted heterocycloalkyl; m is 1, 2, 3, or 4, and each R.sup.10 may be the same or different when m is 2, 3, or 4; and R.sup.10 is selected from the group consisting of cyano, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, --CF.sub.3, alkoxy, substituted alkoxy, halo, and hydroxy; and R.sup.11 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, --SO.sub.2alkyl, and --SO.sub.2 substituted alkyl. 6. A compound of claim 5, having Formula (IIb) or a pharmaceutically acceptable salt, ester, or prodrug thereof: ##STR00174## 7. A compound according to any one of claim 1, 3, or 5, wherein R.sup.1 is alkyl. 8. A compound of claim 7 wherein R.sup.1 is selected from the group consisting of isopropyl, t-butyl, and propyl. 9. A compound according to any one of claim 1, 3, or 5, wherein A.sup.1 is aryl or substituted aryl. 10. A compound of claim 9, wherein A.sup.1 is substituted or unsubstituted phenyl. 11. A compound according to any one of claim 1, 3, or 5, wherein A.sup.1 is heteroaryl or substituted heteroaryl. 12. A compound of claim 11, wherein A.sup.1 is substituted or unsubstituted pyridyl. 13. A compound according to any one of claim 1, 3, or 5, wherein A.sup.1 is heterocycloalkyl or substituted heterocycloalkyl. 14. A compound of claim 13, wherein A.sup.1 is substituted or unsubstituted morpholino. 15. A compound according to any one of claim 1, 3, or 5, wherein A.sup.1 is alkyl or substituted alkyl. 16. A compound of claim 15, wherein said substituted alkyl is substituted with alkoxy or hydroxy. 17. A compound according to any one of claim 1, 3, or 5, wherein A.sup.1 is 1,3-benzothiadiazol-4-yl, t-butoxy, butoxy, n-butoxy, cyclohexyl, 2,2-dimethylpropoxy, ethoxy, furan-3-yl, isoxazol-3-yl, methoxy, methyl, 2-methylpropoxy, phenyl, piperidin-3-yl, piperidin-4-yl, n-propoxy, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrazin-2-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydro-2H-pyran-4-yl, 1H-tetrazol-1-yl, 2H-tetrazol-2-yl, thiazol-4-yl, 1,3,4-thiadiazol-2-yl, 1,3-benzothiadiazol-6-yl, 3,3-dihydrobenzo[1,2,3]thiadiazol-4-yl, benzimidazol-2-yl, benzimidazol-6-yl, benzo[1,2,5]thiadiazole, benzoxadiazol-4-yl, cyclopentyl, imidazol-4-yl, indazol-6-y, isooxazol-5-yl, morpholin-2-yl, morpholino, oxazol-4-yl, piperidin-N-yl, pyrazol-3-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrrolidin-N-yl, tetrazol-5-yl, or thiadiazol-4-yl. 18. A compound according to any one of claim 1, 3, or 5, wherein A.sup.1 is a substituted aryl or heteroaryl group selected from the group consisting of 5-methyl-2H-imidazol-4-yl, 2-aminothiazol-4-yl, 4-t-butylphenyl, 2-chlorophenyl, 2-chloro-6-methylpyrid-4-yl, 3-chlorophenyl, 4-chlorophenyl, 6-chloropyridin-3-yl, 3,4-dichlorophenyl, 2,4-difluorophenyl, 1,5-dimethyl-1H-pyrazol-3-yl, 2,4-dimethylthiazol-5-yl, 1-ethyl-3-methyl-1H-pyrazol-5-yl, 2-methoxyphenyl, 4-methoxyphenyl, 4-methylisoxazol-3-yl, 5-methylisoxazol-4-yl, 4-methylphenyl, 1-methyl-3-trifluoromethyl-1H-pyrazol-4-yl, 1-methyl-5-chloro-1H-pyrazol-4-yl, 5-methyl-1H-pyrazol-3-yl, 6-methylpyridin-3-yl, 2-pyrrolidin-3-ylphenyl, 4-(trifluoromethyl)phenyl, 6-(trifluoromethyl)pyridin-3-yl, 2,5-dimethyloxazol-4-yl, 2-aminothiazol-4-yl, 4-methylpyrazol-5-yl, 3-trifluoromethylpyrazol-4-yl, 2-methyl-3-trifluoromethylpyrazol-5-yl, 4-chloro-1,3-dimethylpyrazolo[3,4]pyridine, and 1-methylbenzimidazol-2-yl. 19. A compound according to any one of claim 1, 3, or 5, wherein A.sup.1 is a substituted heterocyclic or cycloalkyl selected from the group consisting of 3-[(aminoacetyl)amino]cyclohexyl, 3-(2-aminoethylsulfonylamino)cyclohexyl, 1-methylpiperazin-4-yl, 1-methylcarbonylpiperidin-4-yl, 1-methoxycarbonylpiperidin-4-yl, quinuclidin-3-yl, 2-oxopyrrolidin-5-yl, 2-oxopyrrolidin-4-yl, 2-oxo-dihydrofuran-5-yl, 2-oxothiazolidin-4-yl, and 3-hydroxypyrrolidin-5-yl. 20. A compound according to any one of claim 1, 3, or 5, wherein A.sup.1 is a substituted alkyl selected from the group consisting of 3-amino-2-oxo-1(2H)-pyridinylmethyl, cyanomethyl, (N,N-dimethylamino)methyl, ethoxymethyl, p-fluorophenoxymethyl, hydroxymethyl, 1H-imidazol-1-ylmethyl, methoxymethyl, (N-methylamino)methyl, methylsulfonylmethyl, (5-methyl-1H-tetrazol-1-yl)methyl, (5-methyl-2H-tetrazol-2-yl)methyl, morpholin-4-ylmethyl, 1H-pyrazol-1-ylmethyl, 1H-1,2,3-triazol-1-ylmethyl, 2H-1,2,3-triazol-2-ylmethyl, 1H-1,2,4-triazol-1-ylmethyl, 2H-1,2,4-triazol-2-ylmethyl, 4H-1,2,4-triazol-4-ylmethyl, 1H-tetrazol-1-ylmethyl, 1H-tetrazol-5-ylmethyl, 2H-tetrazol-2-ylmethyl, imidazol-4-ylmethyl, 1-methylpyrazol-3-ylmethyl, piperidin-4-ylmethyl, trifluoromethyl, dimethylaminoethyl, and 2-oxo-3-aminopyrrolidin-1-ylmethyl. 21. A compound according to any one of claim 1, 3, or 5, wherein A.sup.1 is NR.sup.8R.sup.9. 22. A compound of claim 21, wherein R.sup.8 is hydrogen. 23. A compound of claim 21, wherein R.sup.8 and R.sup.9 are hydrogen. 24. A compound of claim 21, wherein R.sup.9 is selected from the group consisting of alkyl, substituted alkyl, and cycloalkyl. 25. A compound of claim 24, wherein R.sup.9 is selected from the group consisting of methyl, hydroxymethyl, methoxymethyl, methoxyethyl, furan-2-ylmethyl, 2-hydroxyethyl, cyclopropyl and isopropyl. 26. A compound of claim 21, wherein R.sup.9 is aryl or substituted aryl. 27. A compound of claim 26, wherein R.sup.9 is selected from the group consisting of 4-cyanophenyl, 3,4-difluorophenyl, 2,3,5-trifluorophenyl, 3,5-dinitrophenyl, and phenyl. 28. A compound of claim 21, wherein R.sup.9 is heteroaryl or substituted heteroaryl. 29. A compound of claim 28, wherein R.sup.9 is selected from the group consisting of thiophen-2-yl, 3,5-dimethylisoxazol-4-yl, and 2,6-dichloropyridin-4-yl. 30. A compound of claim 21, wherein R.sup.9 is a heterocycloalkyl or substituted heterocycloalkyl group. 31. A compound of claim 30, wherein R.sup.9 is tetrahydropyran-4-yl or 4-(ethoxycarbonyl)piperidin-4-yl. 32. A compound of claim 21, wherein R.sup.9 is a hydroxy. 33. A compound of claim 21, wherein R.sup.8 and R.sup.9 are cyclized with the nitrogen atom bound thereto to form a heterocyclic or substituted heterocyclic --NR.sup.8R.sup.9 that is selected from the group consisting of thiamorpholin-N-yl, 1,1-dioxothiamorpholin-N-yl, 1-oxothiamorpholin-1-yl, 2-(aminomethylene)pyrrolidin-N-yl, 2-(methoxycarbonyl)pyrrolidin-N-yl, 2,6-dimethylmorpholin-N-yl, 3-hydroxypiperidin-N-yl, 3-hydroxypyrrolidin-N-yl, 4-(butylsulfonyl)piperazin-N-yl, 4-(cyclopropylsulfonyl)piperazin-N-yl, 4-(dimethylamino)piperidin-N-yl, 4-(ethoxycarbonyl)piperazin-N-yl, 4-(ethylsulfonyl)piperazin-N-yl, 4-(isopropylsulfonyl)piperazin-N-yl, 4-(methylcarbonyl)piperazin-N-yl, 4-(methylsulfonyl)piperidin-N-yl, 4-(methysulfonyl)piperazin-N-yl, 4-(morpholin-N-yl)piperidin-N-yl, 4-(propylsulfonyl)piperazin-N-yl, 4-cyclohexylpiperazin-N-yl, 4-hydroxypiperidin-N-yl, 4-isopropylpiperazin-4-yl, 4-methylpiperidin-N-yl, isoxazolidin-2-yl, morpholin-N-yl, piperazin-N-yl, piperidin-N-yl, 2-(hydrazinocarbonyl)pyrrolidin-N-yl, and pyrrolidin-N-yl. 34. A compound according to any one of claim 1, 3, or 5, wherein R.sup.4 is substituted alkyl. 35. A compound of claim 34, wherein R.sup.4 is alkyl substituted with 1 to 5 substituents selected from the group consisting of amino, substituted amino, halo, alkoxy, substituted alkoxy, and hydroxy. 36. A compound according to any one of claim 1, 3, or 5, wherein R.sup.4 is selected from the group consisting of hydrogen, piperidin-4-yl, --(CH.sub.2).sub.2--NH.sub.2, --CH.sub.2-azetidin-3-yl, --CH.sub.2-(2,5-dihydropyrrol-3-yl), --(CH.sub.2).sub.3-imidazol-1-yl, --CH.sub.2-(1H-imidazol-4-yl), --CH.sub.2-pyridin-3-yl, --CH.sub.2-(2-hydroxypyridin-4-yl), --CH.sub.2-(6-hydroxypyridin-3-yl), --CH.sub.2-morpholin-2-yl, --CH.sub.2-pyrrolidin-3-yl, --CH.sub.2-(3-fluoropyrrolidin-3-yl), --CH.sub.2-(3-hydroxypyrrolidin-3-yl), --CH.sub.2-(4-fluoropyrrolidin-3-yl), --CH.sub.2-(4-hydroxypyrrolidin-3-yl), --CH.sub.2-(2-hydroxymethylpyrrolidin-3-yl), --CH.sub.2-piperidin-3-yl, --CH.sub.2-[1H-(1,2,3-triazol-4-yl)], --CH.sub.2CH(NH.sub.2)CH.sub.2OH, --(CH.sub.2).sub.3--OH, --(CH.sub.2).sub.3--O(CO)-phenyl, --(CH.sub.2).sub.3--NH.sub.2, --(CH.sub.2).sub.3--NHCH.sub.3, --(CH.sub.2).sub.3--N(CH.sub.3).sub.2, --(CH.sub.2).sub.3--NHOCH.sub.3, --(CH.sub.2).sub.3--NHSO.sub.2CH.sub.3, --(CH.sub.2).sub.3NH-(5-cyanopyridin-2-yl), --(CH.sub.2).sub.3NH-cyclopropyl, --(CH.sub.2).sub.3NH-cyclobutyl, --(CH.sub.2).sub.3-(1H-imidazol-2-yl), --(CH.sub.2).sub.3-(2-hydroxyethylpiperidin-1-yl), --(CH.sub.2).sub.3NH(2-hydroxymethylphenyl), --(CH.sub.2).sub.3NH-(5-trifluoromethylpyridin-2-yl), --(CH.sub.2).sub.3NHCH.sub.2-cyclopropyl, --(CH.sub.2).sub.3NHCH.sub.2-{5-(pyridin-3-yloxy)-1H-indazol-3-yl}, --(CH.sub.2).sub.3NHCH.sub.2-(5-methoxy-1H-indazol-3-yl), --(CH.sub.2).sub.3NHCH.sub.2-(6-fluoro-1H-indazol-3-yl), --CH.sub.2CHOHCH.sub.2NH.sub.2, --CH.sub.2CH(CH.sub.2OH)CH.sub.2NH.sub.2, --CH.sub.2C(CH.sub.3).sub.2CH.sub.2--N(CH.sub.3).sub.2, --CH.sub.2C(CH.sub.3).sub.2CH.sub.2-(4-methylpiperazin-1-yl), --(CH.sub.2).sub.2C(O)NH.sub.2, --(CH.sub.2).sub.2CH(NH.sub.2)C(O)NH.sub.2, --(CH.sub.2).sub.2CH(NH.sub.2)C(O)OH, --(CH.sub.2).sub.2CH(NH.sub.2)CH.sub.2C(O)NH.sub.2, --(CH.sub.2).sub.2CH(NH.sub.2)CH.sub.2OH, --(CH.sub.2).sub.2CH(NH.sub.2)CH.sub.3, --(CH.sub.2).sub.3NHC(O)CH.sub.2NH.sub.2, --(CH.sub.2).sub.3NHC(O)CH(NH.sub.2)CH(CH.sub.3).sub.2, --CH.sub.2CHFCH.sub.2NH.sub.2, --(CH.sub.2).sub.2NHC(O)CH.sub.2NH.sub.2, --(CH.sub.2).sub.3--NHCH.sub.2CH.sub.2OH, --(CH.sub.2).sub.3--NHCH.sub.2CO.sub.2H, --(CH.sub.2).sub.3NHCH.sub.2CO.sub.2CH.sub.2CH.sub.3, --(CH.sub.2).sub.3--N(CH.sub.2CH.sub.2OH).sub.2, --(CH.sub.2).sub.3--NHCH(CH.sub.2OH).sub.2, --(CH.sub.2).sub.3CH.sub.3, --(CH.sub.2).sub.2CH(NH.sub.2)CH.sub.2OH, --(CH.sub.2).sub.2C(CH.sub.3).sub.2NH.sub.2, --(CH.sub.2).sub.2CH(NH.sub.2)CH.sub.2OCH.sub.3, --(CH.sub.2).sub.2CH(NH.sub.2)CH.sub.2F, --CH.sub.2CHFCH(NH.sub.2)CH.sub.2OH, and --(CH.sub.2).sub.2spirocylcopropyl-NH.sub.2. 37. A compound according to any one of claim 1, 3, or 5, wherein R.sup.4 is selected from the group consisting of --(CH.sub.2).sub.3NH.sub.2, --(CH.sub.2).sub.2CH(CH.sub.2OH)NH.sub.2, --CH.sub.2CH(F)CH.sub.2NH.sub.2, --CH.sub.2-[2-(CH.sub.2OH)pyrrolidin-3-yl], --CH.sub.2-[4-(OH)pyrrolidin-3-yl], --CH.sub.2--C(F)(spiropyrrolidin-3-yl), --(CH.sub.2).sub.2CH(CH.sub.2F)NH.sub.2, --(CH.sub.2).sub.2C(CH.sub.3).sub.2NH.sub.2, --(CH.sub.2).sub.2CH(CH.sub.3)NH.sub.2, and --(CH.sub.2)CH(CH.sub.2OCH.sub.3)NH.sub.2. 38. A compound according to any one of claim 1, 3, or 5, wherein R.sup.3 and R.sup.4 or A.sup.1 and R.sup.4 together with the atoms bound respectively thereto join to form a five to seven membered heterocycloalkyl or substituted heterocycloalkyl group. 39. A compound of claim 38, wherein the heterocycloalkyl or substituted heterocycloalkyl group is selected from the group consisting of: ##STR00175## ##STR00176## ##STR00177## 40. A compound according to any one of claim 1, 3, or 5, wherein R.sup.6 is aryl or substituted aryl and is selected from the group consisting of phenyl, 3-chlorophenyl, 3-fluorophenyl, 2,5-difluorophenyl, and 2,3,5-trifluorophenyl. 41. A compound according to any one of claim 1, 3, or 5, wherein R.sup.6 is selected from the group consisting of phenyl, 3-bromophenyl, 3-chlorophenyl, 4-cyanophenyl, 3,5-difluorophenyl, 3-fluorophenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-methylphenyl, pyrazin-2-yl, pyridin-2-yl, thiazol-2-yl, 2-trifluoromethylphenyl, and 3-trifluoromethylphenyl. 42. A compound according to any one of claim 1, 3, or 5, wherein A.sup.2 is selected from the group consisting of phenyl, 6-aminopyridin-2-yl, 3-chlorophenyl, 3-cyanophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 3,5-difluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3-hydroxyphenyl, 3-methoxyphenyl, 1-(5-methyl)-isoxazol-3-yl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, tetrahydropyran-4-yl, thiazol-4-yl, and 5-trifluoromethylfuran-2-yl. 43. A compound according to any one of claim 1, 3, or 5, wherein L.sup.2 is methylene and A.sup.2 is selected from the group consisting of phenyl, 3-fluorophenyl, or 3-hydroxyphenyl. 44. A compound according to any one of claim 1, 3, or 5, wherein R.sup.7 is benzyl. 45. A compound according to any one of claim 1, 3, or 5, wherein R.sup.1 is t-butyl, L.sup.2 is methylene, A.sup.2 is phenyl, and R.sup.6 is phenyl or substituted phenyl. 46. A compound of claim 45, wherein R.sup.1 is t-butyl, L.sup.2 is methylene, A.sup.1 is phenyl, R.sup.6 is phenyl substituted with 1 to 2 halo substituents. 47. A compound according to any one of claim 1, 3, or 5, wherein R.sup.1 is t-butyl, R.sup.2 is hydrogen, L.sup.2 is methylene, A.sup.2 is phenyl, R.sup.4 is substituted alkyl. 48. A compound of claim 47, wherein R.sup.4 is --(CH.sub.2).sub.3NH.sub.2, --CH.sub.2CH(F)CH.sub.2NH.sub.2, --(CH.sub.2).sub.2CH(CH.sub.2F)NH.sub.2, --(CH.sub.2).sub.2CH(CH.sub.2OCH.sub.3)NH.sub.2, --(CH.sub.2).sub.2CH(CH.sub.3)NH.sub.2, --(CH.sub.2).sub.2C(CH.sub.3).sub.2NH.sub.2 or --(CH.sub.2).sub.2CH(CH.sub.2OH)NH.sub.2. 49. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier. 50. The composition of claim 49 further comprising at least one additional agent for the treatment of cancer. 51. The composition of claim 50, wherein the additional agent for the treatment of cancer is selected from the group consisting of irinotecan, topotecan, gemcitabine, imatinib, trastuzumab, 5-fluorouracil, leucovorin, carboplatin, cisplatin, docetaxel, paclitaxel, tezacitabine, cyclophosphamide, vinca alkaloids, anthracyclines, rituximab, and trastuzumab. 52. A compound of claim 1 selected from N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(2,5-difluorophenyl)- -1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)nicotinamide; N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(2,5-difluorophenyl)- -1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)morpholine-4-carboxamide; N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(2,5-difluorophenyl)- -1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2-methoxyacetamide; N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(2,5-difluorophenyl)- -1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2-hydroxyacetamide; N--((R)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(2,5-difluorophenyl)- -1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)piperidine-1-carboxamide; N--((R)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(2,5-difluorophenyl)- -1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)morpholine-4-carboxamide; (2S,6R)--N--((R)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(2,5-difluo- rophenyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2,6-dimethylmorpholin- e-4-carboxamide; 1-((R)-3-amino-4-fluorobutyl)-1-((R)-1-(1-benzyl-3-(2,5-difluorophenyl)-1- H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-3,3-dimethyl urea; 1-((R)-3-amino-4-fluorobutyl)-1-((R)-1-(1-benzyl-3-(2,5-difluorophenyl)-1- H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-3-methylurea; (2S,6R)--N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(2,5-difluo- rophenyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2,6-dimethylmorpholin- e-4-carboxamide; 1-((S)-3-amino-4-fluorobutyl)-1-((R)-1-(1-benzyl-3-(2,5-difluorophenyl)-1- H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-3,3-dimethylurea; 1-((S)-3-amino-4-fluorobutyl)-1-(R)-1-(1-benzyl-3-(2,5-difluorophenyl)-1H- -1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-3-methylurea; N--((R)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(2,5-difluorophenyl)- -1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)thiomorpholine-4-carboxamide; N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(2,5-difluorophenyl)- -1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)thiomorpholine-4-carboxamide; N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(2,5-difluorophenyl)- -1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)piperidine-1-carboxamide; (R)-6-(aminomethyl)-4-((R)-1-(1-benzyl-3-phenyl-1H-1,2,4-triazol-5-yl)-2,- 2-dimethylpropyl)-1,4-oxazepan-3-one; and (S)-6-(aminomethyl)-4-((R)-1-(1-benzyl-3-(2,5-difluorophenyl)-1H-1,2,4-tr- iazol-5-yl)-2,2-dimethylpropyl)-1,4-oxazepan-3-one; or a pharmaceutically acceptable salt, ester, or prodrug thereof. 53. A compound of claim 1 selected from N--((R)-3-amino-4-fluorobutyl)-N--((R)-1-(2-benzyl-5-(2,5-difluorophenyl)- -2H-1,2,4-triazol-3-yl)-2,2-dimethylpropyl)-2-hydroxyacetamide; N--((R)-3-amino-4-fluorobutyl)-N--((R)-1-(2-benzyl-5-(2,5-difluorophenyl)- -2H-1,2,4-triazol-3-yl)-2,2-dimethylpropyl)nicotinamide; N--((R)-3-amino-4-fluorobutyl)-N--((R)-1-(2-benzyl-5-(2,5-difluorophenyl)- -2H-1,2,4-triazol-3-yl)-2,2-dimethylpropyl)-1,1-dioxothiomorpholine-4-carb- oxamide; N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(2-benzyl-5-(2,5-difluor- ophenyl)-2H-1,2,4-triazol-3-yl)-2,2-dimethylpropyl)-1,1-dioxothiomorpholin- e-4-carboxamide; (2R)--N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(2-benzyl-5-(2,5-difluorop- henyl)-2H-1,2,4-triazol-3-yl)-2,2-dimethylpropyl)-2-(hydroxymethyl)pyrroli- dine-1-carboxamide; (2S)--N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(2-benzyl-5-(2,5-difluorop- henyl)-2H-1,2,4-triazol-3-yl)-2,2-dimethylpropyl)-2-(hydroxymethyl)pyrroli- dine-1-carboxamide; (2R)--N--((R)-3-amino-4-fluorobutyl)-N--((R)-1-(2-benzyl-5-(2,5-difluorop- henyl)-2H-1,2,4-triazol-3-yl)-2,2-dimethylpropyl)-2-(hydroxymethyl)pyrroli- dine-1-carboxamide; (2S)--N--((R)-3-amino-4-fluorobutyl)-N--((R)-1-(2-benzyl-5-(2,5-difluorop- henyl)-2H-1,2,4-triazol-3-yl)-2,2-dimethylpropyl)-2-(hydroxymethyl)pyrroli- dine-1-carboxamide; (2S)--N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(2-benzyl-5-(2,5-difluorop- henyl)-2H-1,2,4-triazol-3-yl)-2,2-dimethylpropyl)-2-hydroxypropanamide; N-(3-aminopropyl)-N--((R)-1-(2-benzyl-5-(2,5-difluorophenyl)-2H-1,2,4-tri- azol-3-yl)-2,2-dimethylpropyl)nicotinamide; (2S)--N-(3-aminopropyl)-N--((R)-1-(2-benzyl-5-(2,5-difluorophenyl)-2H-1,2- ,4-triazol-3-yl)-2,2-dimethylpropyl)-2-hydroxypropanamide; N-(3-aminopropyl)-N--((R)-1-(2-benzyl-5-(2,5-difluorophenyl)-2H-1,2,4-tri- azol-3-yl)-2,2-dimethylpropyl)-2-hydroxyacetamide; (2S)--N-(3-aminopropyl)-N--((R)-1-(2-benzyl-5-(2,5-difluorophenyl)-2H-1,2- ,4-triazol-3-yl)-2,2-dimethylpropyl)-2-(hydroxymethyl)pyrrolidine-1-carbox- amide; N-(3-aminopropyl)-N--((R)-1-(2-benzyl-5-(2,5-difluorophenyl)-2H-1,2- ,4-triazol-3-yl)-2,2-dimethylpropyl)morpholine-4-carboxamide; (2S,6R)--N-(3-aminopropyl)-N--((R)-1-(2-benzyl-5-(2,5-difluorophenyl)-2H-- 1,2,4-triazol-3-yl)-2,2-dimethylpropyl)-2,6-dimethylmorpholine-4-carboxami- de; N-(3-aminopropyl)-N--((R)-1-(2-benzyl-5-(2,5-difluorophenyl)-2H-1,2,4-- triazol-3-yl)-2,2-dimethylpropyl)-4-(methylsulfonyl)piperazine-1-carboxami- de; (2S)--N--((R)-3-amino-4-fluorobutyl)-N--((R)-1-(2-benzyl-5-(2,5-difluo- rophenyl)-2H-1,2,4-triazol-3-yl)-2,2-dimethylpropyl)-2-hydroxypropanamide; (2S)--N--((S)-3-amino-2-fluoropropyl)-N--((R)-1-(2-benzyl-5-(2,5-difluoro- phenyl)-2H-1,2,4-triazol-3-yl)-2,2-dimethylpropyl)-2-(hydroxymethyl)pyrrol- idine-1-carboxamide; (2S,6R)--N--((S)-3-amino-2-fluoropropyl)-N--((R)-1-(2-benzyl-5-(2,5-diflu- orophenyl)-2H-1,2,4-triazol-3-yl)-2,2-dimethylpropyl)-2,6-dimethylmorpholi- ne-4-carboxamide; N--((S)-3-amino-2-fluoropropyl)-N--((R)-1-(2-benzyl-5-(2,5-difluorophenyl- )-2H-1,2,4-triazol-3-yl)-2,2-dimethylpropyl)-2-hydroxyacetamide; (2S)--N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(2-benzyl-5-(2,5-di fluorophenyl)-2H-1,2,4-triazol-3-yl)-2,2-dimethylpropyl)-tetrahydrofuran-- 2-carboxamide; (2S)--N--((R)-3-amino-4-fluorobutyl)-N--((R)-1-(2-benzyl-5-(2,5-difluorop- henyl)-2H-1,2,4-triazol-3-yl)-2,2-dimethylpropyl)-tetrahydrofuran-2-carbox- amide; N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(2-benzyl-5-(2,5-difluorop- henyl)-2H-1,2,4-triazol-3-yl)-2,2-dimethylpropyl)-6-methylpyridine-3-carbo- xamide; N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(2-benzyl-5-(2,5-difluoro- phenyl)-2H-1,2,4-triazol-3-yl)-2,2-dimethylpropyl)isonicotinamide; N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(2-benzyl-5-(2,5-difluorophenyl)- -2H-1,2,4-triazol-3-yl)-2,2-dimethylpropyl)picolinamide; N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(2-benzyl-5-(2,5-difluorophenyl)- -2H-1,2,4-triazol-3-yl)-2,2-dimethylpropyl)-2-(methylsulfonyl)acetamide; N--((S)-3-amino-2-fluoropropyl)-N--((R)-1-(2-benzyl-5-(2,5-difluorophenyl- )-2H-1,2,4-triazol-3-yl)-2,2-dimethylpropyl)nicotinamide; (2S)--N--((S)-3-amino-2-fluoropropyl)-N--((R)-1-(2-benzyl-5-(2,5-difluoro- phenyl)-2H-1,2,4-triazol-3-yl)-2,2-dimethylpropyl)-2-hydroxypropanamide; N--((R)-1-(2-(3-bromobenzyl)-5-(2,5-difluorophenyl)-2H-1,2,4-triazol-3-yl- )-2,2-dimethylpropyl)-N--((S)-3-amino-4-fluorobutyl)-2-hydroxyacetamide (2S)--N--((R)-1-(2-(3-bromobenzyl)-5-(2,5-difluorophenyl)-2H-1,2,4-triazo- l-3-yl)-2,2-dimethylpropyl)-N--((S)-3-amino-4-fluorobutyl)-2-hydroxypropan- amide; N--((R)-1-(2-(3-bromobenzyl)-5-(2,5-difluorophenyl)-2H-1,2,4-triazo- l-3-yl)-2,2-dimethylpropyl)-N--((S)-3-amino-4-fluorobutyl)nicotinamide; N--((R)-1-(2-(3-bromobenzyl)-5-(2,5-difluorophenyl)-2H-1,2,4-triazol-3-yl- )-2,2-dimethylpropyl)-N--((S)-3-amino-4-fluorobutyl)benzamide; N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(2-benzyl-5-(5-chloro-2-fluoroph- enyl)-2H-1,2,4-triazol-3-yl)-2,2-dimethylpropyl)-2-methoxyacetamide; N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(2-benzyl-5-(5-chloro-2-fluoroph- enyl)-2H-1,2,4-triazol-3-yl)-2,2-dimethylpropyl)-2-hydroxyacetamide; (S)--N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(5-chloro-2-flu- orophenyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2-hydroxypropanamide- ; N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(5-chloro-2-fluorop- henyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)benzamide; N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(5-chloro-2-fluoroph- enyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-4-methylbenzamide; N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(5-chloro-2-fluoroph- enyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)nicotinamide; (R)--N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-(3-bromobenzyl)-3-(2,5-d- ifluorophenyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)tetrahydrofuran-2- -carboxamide; (S)--N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-(3-bromobenzyl)-3-(2,5-d- ifluorophenyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)tetrahydrofuran-2- -carboxamide; (R)--N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(2,5-difluoroph- enyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)tetrahydrofuran-2-carboxam- ide; (S)--N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-(3-cyanobenzyl)-3-(2- ,5-difluorophenyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2-hydroxypro- panamide; N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(5-chloro-2- -fluorophenyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)morpholine-4-carb- oxamide; (2S,6R)--N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(5-- chloro-2-fluorophenyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2,6-dime- thylmorpholine-4-carboxamide; N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(5-chloro-2-fluoroph- enyl)-1H-1,2,4-triazol-5-yl)-2-methylpropyl)benzamide; N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(5-chloro-2-fluoroph- enyl)-1H-1,2,4-triazol-5-yl)-2-methylpropyl)-4-methylbenzamide N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(5-chloro-2-fluoroph- enyl)-1H-1,2,4-triazol-5-yl)-2-methylpropyl)-2-methoxyacetamide; N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(5-chloro-2-fluoroph- enyl)-1H-yl)-2-methylpropyl)-2-hydroxyacetamide; (S)--N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(5-chloro-2-flu- orophenyl)-1H-1,2,4-triazol-5-yl)-2-methylpropyl)-2-hydroxypropanamide; (S)--N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(2,5-difluoroph- enyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2-methoxypropanamide; (S)--N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(3-(2,5-difluorophenyl)-1-(- 3-methylbenzyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2-hydroxypropan- amide; (2S,6R)--N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(3-(2,5-difluorop- henyl)-1-(3-methylbenzyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2,6-d- imethylmorpholine-4-carboxamide; (S)--N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(3,5-difluoroph- enyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2-hydroxypropanamide; (S)--N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(3,5-dichloroph- enyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2-hydroxypropanamide; (2S,6R)--N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(3,5-difluo- rophenyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2,6-dimethylmorpholin- e-4-carboxamide; (S)--N--((S)-3-amino-4,4-difluorobutyl)-N--((R)-1-(1-benzyl-3-(2,5-difluo- rophenyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2-hydroxypropanamide; (S)--N--((R)-3-amino-4,4-difluorobutyl)-N--((R)-1-(1-benzyl-3-(2,5-difluo- rophenyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2-hydroxypropanamide; (S)--N--((R)-3-amino-4,4-difluorobutyl)-N--((R)-1-(3-(2,5-difluorophenyl)- -1-(3-methylbenzyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2-hydroxypr- opanamide; (S)--N--((S)-3-amino-4,4-difluorobutyl)-N--((R)-1-(1-(3-cyanobe- nzyl)-3-(2,5-difluorophenyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2-- hydroxypropanamide; (S)--N--((R)-3-amino-4,4-difluorobutyl)-N--((R)-1-(1-(3-cyanobenzyl)-3-(2- ,5-difluorophenyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2-hydroxypro- panamide; (S)--N--((R)-3-amino-4,4-difluorobutyl)-N--((R)-1-(3-(2,5-difluo- rophenyl)-1-(3-(trifluoromethyl)benzyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethy- lpropyl)-2-hydroxypropanamide; (S)--N--((S)-3-amino-4,4-difluorobutyl)-N--((R)-1-(3-(2,5-difluorophenyl)- -1-(3-methylbenzyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2-hydroxypr- opanamide; (S)--N--((S)-3-amino-4,4-difluorobutyl)-N--((R)-1-(3-(2,5-diflu- orophenyl)-1-(3-(trifluoromethyl)benzyl)-1H-1,2,4-triazol-5-yl)-2,2-dimeth- ylpropyl)-2-hydroxypropanamide; (S)--N--((S)-3-amino-4,4-difluorobutyl)-N--((R)-1-(1-(3-bromobenzyl)-3-(2- ,5-difluorophenyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2-hydroxypro- panamide; (S)--N--((R)-3-amino-4,4-difluorobutyl)-N--((R)-1-(1-(3-bromoben- zyl)-3-(2,5-difluorophenyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2-h- ydroxypropanamide; (S)--N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(2-chloro-5-flu- orophenyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2-hydroxypropanamide- ; (S)--N--((S)-3-amino-4-fluorobutyl)-N--((R)-1-(1-benzyl-3-(5-chloro-2-fl- uorophenyl)-1H-1,2-yl)-2-methylpropyl)-3-(hydroxymethyl)morpholine-4-carbo- xamide; (S)--N--((S)-3-amino-4,4-difluorobutyl)-N--((R)-1-(3-(2,5-difluoro- phenyl)-1-(3-isopropylbenzyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2- -hydroxypropanamide; and (S)--N--((R)-3-amino-4,4-difluorobutyl)-N--((R)-1-(3-(2,5-difluorophenyl)- -1-(3-isopropylbenzyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)-2-hydrox- ypropanamide; or a pharmaceutically acceptable salt, ester, or prodrug thereof.

Details for Patent 7,902,240

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2026-11-13
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2026-11-13
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2026-11-13
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2026-11-13